{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T22:23:20Z","timestamp":1790461400969,"version":"4.1.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2009,6,23]],"date-time":"2009-06-23T00:00:00Z","timestamp":1245715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2009,6,23]],"date-time":"2009-06-23T00:00:00Z","timestamp":1245715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1007\/s10637-009-9280-2","type":"journal-article","created":{"date-parts":[[2009,6,22]],"date-time":"2009-06-22T05:31:31Z","timestamp":1245648691000},"page":"523-528","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors"],"prefix":"10.1007","volume":"28","author":[{"given":"Darren R.","family":"Feldman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Turkula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle S.","family":"Ginsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Ishill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujata","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryann","family":"Carousso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George J.","family":"Bosl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Motzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,6,23]]},"reference":[{"key":"9280_CR1","doi-asserted-by":"publisher","first-page":"5493","DOI":"10.1200\/JCO.2006.08.7882","volume":"24","author":"GV Kondagunta","year":"2006","unstructured":"Kondagunta GV, Motzer RJ (2006) Chemotherapy for advanced germ cell tumors. J Clin Oncol 24:5493\u20135502","journal-title":"J Clin Oncol"},{"key":"9280_CR2","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1200\/JCO.1996.14.10.2638","volume":"14","author":"J Beyer","year":"1996","unstructured":"Beyer J, Kramar A, Mandanas R, Linkesch W, Greinix A, Droz JP, Pico JL, Diehl A, Bokemeyer C, Schmoll HJ, Nichols CR, Einhorn LH, Siegert W (1996) High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J Clin Oncol 14:2638\u20132645","journal-title":"J Clin Oncol"},{"key":"9280_CR3","first-page":"1745","volume":"20","author":"DR Feldman","year":"2006","unstructured":"Feldman DR, Motzer RJ (2006) Novel targets and therapies for metastatic renal cell carcinoma. Oncology 20:1745\u20131753. Williston Park, N.Y, discussion 1756","journal-title":"Oncology"},{"key":"9280_CR4","first-page":"577","volume":"13","author":"G Viglietto","year":"1996","unstructured":"Viglietto G, Romano A, Maglione D, Rambaldi M, Paoletti I, Lago CT, Califano D, Monaco C, Mineo A, Santelli G, Manzo G, Botti G, Chiappetta G, Persico MG (1996) Neovascularization in human germ cell tumors correlates with a marked increase in the expression of the vascular endothelial growth factor but not the placenta-derived growth factor. Oncogene 13:577\u2013587","journal-title":"Oncogene"},{"key":"9280_CR5","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1002\/(SICI)1097-0142(19990315)85:6<1323::AID-CNCR15>3.0.CO;2-G","volume":"85","author":"S Fukuda","year":"1999","unstructured":"Fukuda S, Shirahama T, Imazono Y, Tsushima T, Ohmori H, Kayajima T, Take S, Nishiyama K, Yonezawa S, Akiba S, Akiyama S, Ohi Y (1999) Expression of vascular endothelial growth factor in patients with testicular germ cell tumors as an indicator of metastatic disease. Cancer 85:1323\u20131330","journal-title":"Cancer"},{"key":"9280_CR6","first-page":"327","volume":"9","author":"DB Mendel","year":"2003","unstructured":"Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship. Clin Cancer Res 9:327\u2013337","journal-title":"Clin Cancer Res"},{"key":"9280_CR7","doi-asserted-by":"publisher","unstructured":"George S, Blay JY, Casali PG, Le Cesne A, Stephenson P, Deprimo SE, Harmon CS, Law CN, Morgan JA, Ray-Coquard I, Tassell V, Cohen DP, Demetri GD (2009) Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer. doi:10.1016\/j.ejca.2009.02.011","DOI":"10.1016\/j.ejca.2009.02.011"},{"key":"9280_CR8","doi-asserted-by":"crossref","unstructured":"Srinivas S, Roigas J, Gillessen S, Harmenberg U, De Mulder PH, Fountzilas G, Vogelzang N, Peschel C, Flodgren P, Escudier B (2007) Continuous daily administration of sunitinib in patients (pts) with cytokine-refractory metastatic renal cell carcinoma (mRCC): Updated results. Journal of Clinical Oncology, ASCO Annual Meeing Proceedings Part I 25:Abstract 5040","DOI":"10.1200\/jco.2007.25.18_suppl.5040"},{"key":"9280_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1\u201310","journal-title":"Control Clin Trials"},{"key":"9280_CR10","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115\u2013124","journal-title":"N Engl J Med"},{"key":"9280_CR11","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1200\/JCO.2007.13.9303","volume":"26","author":"MA Socinski","year":"2008","unstructured":"Socinski MA, Novello S, Brahmer JR, Rosell R, Sanchez JM, Belani CP, Govindan R, Atkins JN, Gillenwater HH, Pallares C, Tye L, Selaru P, Chao RC, Scagliotti GV (2008) Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 26:650-656","journal-title":"J Clin Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-009-9280-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-009-9280-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-009-9280-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-009-9280-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:38:51Z","timestamp":1678509531000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-009-9280-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,23]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["9280"],"URL":"https:\/\/doi.org\/10.1007\/s10637-009-9280-2","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6,23]]},"assertion":[{"value":"6 May 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2009","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2009","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}